A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 8, 2022

Primary Completion Date

February 24, 2023

Study Completion Date

February 24, 2023

Conditions

Obesity

Interventions

DRUG

LY3437943

Administered SC.

DRUG

Midazolam

Administered orally.

DRUG

Warfarin

Administered orally.

DRUG

Caffeine

Administered orally.

Trial Locations (2)

Covance Clinical Research Unit, Daytona Beach

Covance Dallas, Dallas

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY